10:46 AM EST - Ventripoint Diagnostics Ltd : Provided a corporate update on its business activities. The VMS is approved for the analysis of the right ventricle (RV) of the heart for anyone where the cardiologist deems the information is warranted or desired in the United States, Canada and Europe. The VMS-PLUS™ has recently been approved by Health Canada for the measurement of volumes of the other three chambers of the heart - right atrium (RA), left ventricle (LV) and left atrium (LA).Now that the Company has "home-country" approval, it has been recruiting sales and marketing staff and interviewing potential distributors to assess different markets worldwide for their readiness for the VMS-PLUS. Ventripoint Diagnostics Ltd
shares V.VPT are trading up $0.02 at $0.28.
